SGP started the Liposome R&D since 2015, Ginposome technology is a novel liposome based on Ginsenosides and Lecithin as the membrane instead of Cholesterol and Lecithin. Ginposome comes from Ginsenoside and Liposome. SGP is the first inventor for Ginposome technology, we applied more than 20 related patents, and more than 15 patents were approved, including China, U.S., Europe, Canada, Australia, Japan and India.
Ginposome-Paclitaxel is a First-in-Class NDA, which was Pre-IND in 2020, and IND in 2021. Ginposome-Docetaxel and Ginposome-Cabazitaxel is under developing. Ginposome-Medicines are designed to solve better efficacy, lower toxicity, better targeting, anti-MDR and immunity enhancement.
Ginposome-Nutraceuticals were developed since 2021, scale-up in 2023, Approved in 2024 by FSSC22000, ISO22000 and HACCP. Ginposome-Nutraceuticals are designed to solve better efficacy, higher bioavailability and immunity enhancement.
Best-selling Worldwide
Official Certifications
National Patents
Focus on Liposome
DDS for more than 10 Yeas.
To be the world's leading brand of nutrition and health ingredients
Providing high-quality ingredients and solutions for global nutrition and health companies.
Dedication, Practicalism, Hard working, Keep learning.
If you have any requirements, please contact us freely and we will provide you the best solution.
